X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sterling Biotech with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs NOVARTIS - Comparison Results

STERLING BIOTECH    Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH NOVARTIS STERLING BIOTECH/
NOVARTIS
 
P/E (TTM) x -0.4 292.3 - View Chart
P/BV x 0.0 32.4 0.0% View Chart
Dividend Yield % 0.0 1.4 -  

Financials

 STERLING BIOTECH   NOVARTIS
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
NOVARTIS
Mar-18
STERLING BIOTECH/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs11758 1.4%   
Low Rs3579 0.6%   
Sales per share (Unadj.) Rs26.8228.4 11.7%  
Earnings per share (Unadj.) Rs-15.031.7 -47.1%  
Cash flow per share (Unadj.) Rs-5.532.8 -16.7%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs54.9297.1 18.5%  
Shares outstanding (eoy) m267.8724.69 1,084.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.9 8.9%   
Avg P/E ratio x-0.521.1 -2.2%  
P/CF ratio (eoy) x-1.320.4 -6.2%  
Price / Book Value ratio x0.12.2 5.6%  
Dividend payout %031.5 0.0%   
Avg Mkt Cap Rs m1,86216,505 11.3%   
No. of employees `0001.40.7 202.7%   
Total wages/salary Rs m5471,445 37.8%   
Avg. sales/employee Rs Th5,303.38,441.3 62.8%   
Avg. wages/employee Rs Th403.82,163.6 18.7%   
Avg. net profit/employee Rs Th-2,959.01,173.1 -252.2%   
INCOME DATA
Net Sales Rs m7,1815,639 127.3%  
Other income Rs m431,718 2.5%   
Total revenues Rs m7,2237,357 98.2%   
Gross profit Rs m947-63 -1,515.0%  
Depreciation Rs m2,54325 10,052.2%   
Interest Rs m4,37755 7,915.2%   
Profit before tax Rs m-5,9311,575 -376.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,924792 -243.1%   
Profit after tax Rs m-4,007784 -511.3%  
Gross profit margin %13.2-1.1 -1,189.7%  
Effective tax rate %32.450.3 64.6%   
Net profit margin %-55.813.9 -401.5%  
BALANCE SHEET DATA
Current assets Rs m14,3359,522 150.6%   
Current liabilities Rs m49,8093,296 1,511.2%   
Net working cap to sales %-494.0110.4 -447.5%  
Current ratio x0.32.9 10.0%  
Inventory Days Days40337 1,101.7%  
Debtors Days Days17128 600.4%  
Net fixed assets Rs m55,43246 120,505.0%   
Share capital Rs m268123 217.1%   
"Free" reserves Rs m13,9357,213 193.2%   
Net worth Rs m14,7017,336 200.4%   
Long term debt Rs m9,4780-   
Total assets Rs m73,98811,105 666.2%  
Interest coverage x-0.429.5 -1.2%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.10.5 19.1%   
Return on assets %0.57.6 6.6%  
Return on equity %-27.310.7 -255.2%  
Return on capital %-6.422.2 -28.9%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,86061 3,069.0%   
Fx outflow Rs m253,630 0.7%   
Net fx Rs m1,835-3,570 -51.4%   
CASH FLOW
From Operations Rs m1,7191,610 106.8%  
From Investments Rs m-3,148687 -458.3%  
From Financial Activity Rs m1,426-2,677 -53.3%  
Net Cashflow Rs m-3-380 0.9%  

Share Holding

Indian Promoters % 33.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.0 2.0 -  
FIIs % 9.9 1.6 618.8%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 21.5 182.8%  
Shareholders   21,482 41,647 51.6%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  UNICHEM LAB  

Compare STERLING BIOTECH With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY18); Net Profit Up 809.6% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, NOVARTIS has posted a net profit of Rs 265 m (up 809.6% YoY). Sales on the other hand came in at Rs 1 bn (down 13.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

Tata Chem: Suspension of Haldia Operations Drag Bottomline Lower (Quarterly Results Update - Detailed)

Aug 17, 2017

Interruption at Haldia plant and fire at Lostock facility hits operations during the quarter.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Aug 13, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 8-QTR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS